LeukoVantage® Myeloid testing by Next-Generation Sequencing (NGS)

Because there’s more to monitoring

LeukoVantage^® is an innovative selection of panels that provide confirmatory diagnosis, helping inform prognosis and therapeutic indications for:

Acute myeloid leukemia (AML)
Myeloproliferative neoplasms (MPN)
Myelodysplastic syndrome (MDS)
General Myeloid Panel

LeukoVantage panels utilize the latest in NGS technology, so you and your patients can know more, sooner, and make more informed treatment decisions.

Order LeukoVantage today ➜

Built on recent guidelines

LeukoVantage is a panel that offers physicians testing solutions for these disease states: acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and other myeloid neoplasms. Based on a comprehensive literature review and updated guidelines for gene inclusion from the World Health Organization and National Comprehensive Cancer Network^®, the analyzed genes can help physicians make a more informed diagnosis and more closely monitor disease progression and their patients’ response to treatment.^1-4

These 4 panels can help:

Classify acute myeloid leukemia (AML)
Aid in diagnosis of myeloproliferative neoplasms (MPN)
Make an early assessment of myelodysplastic syndrome (MDS)—detects mutated genes in early MDS when cytogenetics is uninformative³

A comprehensive series of 4 panels that interrogate genes that are guideline-indicated as relevant to myeloid diseases

The LeukoVantage Myeloid Mutation panels utilize NGS technology to reliably detect mutation levels down to 5% allele levels, single nucleotide variants, small insertions, and deletions.

^a Internal tandem duplications and tyrosine kinase codon 835/836 mutations

^b PTD: partial tandem duplication detected by a long-range PCR-based method

Enhanced reporting and ordering for more informed patient care

Our Quanum^® for Healthcare Professionals portal offers enhanced reporting, with clinical annotation and tabular information that can facilitate productive conversations with patients.

Specimen requirements

Type	Room temperature (18ºC-25ºC)	Refrigerated (2ºC-8ºC)	Frozen (-10ºC or lower)
Whole blood	2 weeks^c	2 weeks^c	Not acceptable
Bone marrow	2 weeks^c	2 weeks^c	Not acceptable
Extracted DNA	1 month	2 years	3 years
Cell pellet	1 month	2 years	3 years

^c 1 week if collected in heparin tubes

Click here for test ordering information ➜

To learn more about LeukoVantage, speak with your Quest Diagnostics sales representative or call 1.833.773.1441.

References

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405. doi:10.1182/blood-2016-03-643544
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia, Version 1.2018—February 7, 2018. Accessed July 15, 2018. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myelodysplastic Syndromes, Version 2.2018—February 15, 2018. Accessed July 15, 2018. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myeloproliferative Neoplasms, Version 2.2018—September 7, 2017. Accessed July 15, 2018. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
Rosenthal SE, Gerasimova A, et al. Evaluation of the 42-Gene Next Generation Sequencing Panel for Detection of Acute Myeloid Leukemia Mutations for Clinical Use. Abstract presented at ASCO Annual Scientific Meeting: 2019; Chicago, IL